Yesterday Boehringer Ingelheim won the FDA’s approval for a high-concentration and citrate-free version of its Humira biosimilar Cyltezo, targeting AbbVie’s blockbuster drug.
Tag Archive for: Cyltezo
Despite hitting the market more than a year ago with steep discounts, biosimilars for AbbVie’s blockbuster arthritis treatment Humira (adalimumab) have managed to take only 4% of the market share away from the branded reference product, according to the latest quarterly report from Samsung Bioepis.
Consumer healthcare brand CVS Health on Wednesday launched Cordavis, a wholly owned subsidiary focused on the growing U.S. biosimilars market that will work directly with manufacturers.
AbbVie’s Humira will now face lower-price competition from four new biosimilars: Boehringer Ingelheim’s Cyltezo, Celltrion’s Yuflyma, Organon and Samsung’s Hadlima, and Sandoz’s Hyrimoz.